Search

Your search keyword '"Konstantinov DN"' showing total 3 results
Start Over Author "Konstantinov DN"
3 results on '"Konstantinov DN"'

1. Therapeutic results in three cases of ganglioneuroblastoma associated with opsoclonus myoclonus ataxia syndrome.

Author

Shtarbanov IA, Boronsuzov IK, Chakarov IR, and Konstantinov DN

Subjects
Combined Modality Therapy, Female, Ganglioneuroblastoma complications, Ganglioneuroblastoma pathology, Humans, Infant, Opsoclonus-Myoclonus Syndrome complications, Opsoclonus-Myoclonus Syndrome pathology, Paraneoplastic Syndromes, Nervous System complications, Paraneoplastic Syndromes, Nervous System pathology, Treatment Outcome, Ganglioneuroblastoma therapy, Opsoclonus-Myoclonus Syndrome therapy, Paraneoplastic Syndromes, Nervous System therapy
Abstract

Competing Interests: None

Published
2020
Full Text
View/download PDF

2. Treatment of Childhood Acute Myeloid Leukemia in Bulgaria.

Author

Burnusuzov HA, Yordanova MN, Avramova BE, Yurukova NN, Bachvarov KN, Muchinova AB, Vlahova IH, Stoyanova AA, Mumdzhiev IN, Ivanova LR, Spasov NY, Peteva ET, Belcheva MI, Hristozova H, Spasova MI, Kaleva VI, Bobev D, and Konstantinov DN

Subjects
Adolescent, Asparaginase therapeutic use, Bulgaria epidemiology, Child, Child, Preschool, Daunorubicin therapeutic use, Female, Humans, Infant, Infant, Newborn, Kaplan-Meier Estimate, Leukemia, Myeloid, Acute mortality, Male, Neoplasm Recurrence, Local mortality, Prednisone therapeutic use, Remission Induction, Retrospective Studies, Survival Rate, Vincristine therapeutic use, Young Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute therapy, Neoplasm Recurrence, Local epidemiology
Abstract

Background: During the last four decades the prognosis of childhood acute myeloid leukemia (AML) has been substantially improved due to an increase in complete remission (CR) rates, event-free survival (EFS) and reduced early mortality. The relapsed AML still remains a therapeutic challenge., Aim: To report the AML treatment results of the Bulgarian pediatric oncohematological centers., Materials and Methods: Retrospective analysis of the treatment results of children and adolescents (age from 0 to 20 years) with primary AML. Unified AML BFM- backbone type treatment protocol is used., Results: This study included 97 newly diagnosed patients (44 girls and 53 boys) with AML in Bulgaria between 2003 and 2016. The median age at diagnosis was 10.2 years. The most frequent FAB-morphologic subtype was M2 followed by M4. First complete remission (CR1) was achieved in 83 patients (85.6%). The 13-year EFS was 49%, while the overall survival (OS) was 54.6%. Twenty seven (27.8%) patients relapsed, with only 5 of them being still alive towards the end of the study period., Conclusion: The EFS and OS for the children with AML in Bulgaria are comparable with those reported by other European groups. The prognosis of relapsed AML remains still unfavorable for the past 13 years.

Published
2018
Full Text
View/download PDF

3. Successful mobilization of peripheral blood stem cells in children with cancer using plerixafor (Mozobil) and granulocyte-colony stimulating factor.

Author

Avramova BE, Yordanova MN, Konstantinov DN, and Bobev DG

Subjects
Adolescent, Antigens, CD34 metabolism, Benzylamines, Blood Cell Count, Child, Cyclams, Hematopoietic Stem Cell Mobilization adverse effects, Hematopoietic Stem Cell Mobilization methods, Heterocyclic Compounds adverse effects, Humans, Leukapheresis methods, Male, Transplantation, Autologous, Treatment Outcome, Granulocyte Colony-Stimulating Factor administration & dosage, Heterocyclic Compounds administration & dosage, Neoplasms therapy, Peripheral Blood Stem Cell Transplantation methods
Abstract

This paper describes the successful mobilization of peripheral blood stem cells for autologous transplantation in three children with malignant diseases by using plerixafor (Mozobil; Genzyme Corporation, Cambridge, MA) and granulocyte-colony stimulating factor (G-CSF) after failed previous mobilizations. A median sixfold increase in the number of circulating CD34+ cells after plerixafor treatment as compared with the baseline level was observed. An optimal CD34+ cell count for transplantation with one or two leukapheresis sessions was achieved. Mobilization using plerixafor was found to be safe with no adverse events. Therefore, the combination of G-CSF and plerixafor in children results in effective increases in peripheral CD34+ cell counts and reduces the risk of mobilization failure.

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results